Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diperoxochloric Acid
Therapeutic Area : Podiatry
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Centaur Pharma Launches Novel Topical Solution WoxHeal for the Treatment of Diabetic Foot Ulcer
Details : WOXheal has dual mechanism of action, i.e. it has functional antibacterial action against Gram positive and gram negative bacteria and it also promotes growth of fibroblast cells, thereby yielding complete wound closure.
Product Name : WOXheal
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2020
Lead Product(s) : Diperoxochloric Acid
Therapeutic Area : Podiatry
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VXA-CoV2-1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Vaxart
Deal Size : Undisclosed
Deal Type : Agreement
KindredBio Expands Manufacturing Agreement with Vaxart
Details : The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a wholly owned subsidiary of KindredBio that provides full service contract development and manufacturing services.
Product Name : VXA-CoV2-1
Product Type : Vaccine
Upfront Cash : Undisclosed
July 10, 2020
Lead Product(s) : VXA-CoV2-1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Vaxart
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
